17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Miglustat in Niemann-Pick disease type C patients: a review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive, neurodegenerative disease associated with a wide variety of progressive neurological manifestations. Miglustat is indicated for the treatment of progressive neurological manifestations in both adults and children. Since approval in 2009 there has been a vast growth in clinical experience with miglustat. The effectiveness of miglustat has been assessed using a range of measures.

          Methods

          Comprehensive review of published data from studies of cellular neuropathological markers and structural neurological indices in the brain, clinical impairment/disability, specific clinical neurological manifestations, and patient survival.

          Results

          Cranial diffusion tensor imaging and magnetic resonance spectroscopy studies have shown reduced levels of choline (a neurodegeneration marker), and choline/N-acetyl aspartate ratio (indicating increased neuronal viability) in the brain during up to 5 years of miglustat therapy, as well as a slowing of reductions in fractional anisotropy (an axonal/myelin integrity marker). A 2-year immunoassay study showed significant reductions in CSF-calbindin during treatment, indicating reduced cerebellar Purkinje cell loss. Magnetic resonance imaging studies have demonstrated a protective effect of miglustat on cerebellar and subcortical structure that correlated with clinical symptom severity. Numerous cohort studies assessing core neurological manifestations (impaired ambulation, manipulation, speech, swallowing, other) using NP-C disability scales indicate neurological stabilization over 2–8 years, with a trend for greater benefits in patients with older (non-infantile) age at neurological onset. A randomized controlled trial and several cohort studies have reported improvements or stabilization of saccadic eye movements during 1–5 years of therapy. Swallowing was also shown to improve/remain stable during the randomized trial (up to 2 years), as well as in long-term observational cohorts (up to 6 years). A meta-analysis of dysphagia – a potent risk factor for aspiration pneumonia and premature death in NP-C – demonstrated a survival benefit with miglustat due to improved/stabilized swallowing function.

          Conclusions

          The effects of miglustat on neurological NP-C manifestations has been assessed using a range of approaches, with benefits ranging from cellular changes in the brain through to visible clinical improvements and improved survival.

          Electronic supplementary material

          The online version of this article (10.1186/s13023-018-0844-0) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis.

          Niemann-Pick type C (NP-C) disease, a fatal neurovisceral disorder, is characterized by lysosomal accumulation of low density lipoprotein (LDL)-derived cholesterol. By positional cloning methods, a gene (NPC1) with insertion, deletion, and missense mutations has been identified in NP-C patients. Transfection of NP-C fibroblasts with wild-type NPC1 cDNA resulted in correction of their excessive lysosomal storage of LDL cholesterol, thereby defining the critical role of NPC1 in regulation of intracellular cholesterol trafficking. The 1278-amino acid NPC1 protein has sequence similarity to the morphogen receptor PATCHED and the putative sterol-sensing regions of SREBP cleavage-activating protein (SCAP) and 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification of HE1 as the second gene of Niemann-Pick C disease.

            Niemann-Pick type C2 disease (NP-C2) is a fatal hereditary disorder of unknown etiology characterized by defective egress of cholesterol from lysosomes. Here we show that the disease is caused by a deficiency in HE1, a ubiquitously expressed lysosomal protein identified previously as a cholesterol-binding protein. HE1 was undetectable in fibroblasts from NP-C2 patients but present in fibroblasts from unaffected controls and NP-C1 patients. Mutations in the HE1 gene, which maps to chromosome 14q24.3, were found in NP-C2 patients but not in controls. Treatment of NP-C2 fibroblasts with exogenous recombinant HE1 protein ameliorated lysosomal accumulation of low density lipoprotein-derived cholesterol.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The Child Behavior Checklist and related forms for assessing behavioral/emotional problems and competencies.

                Bookmark

                Author and article information

                Contributors
                +34 932 033 959 , pineda@sjdhospitalbarcelona.org
                Mark.Walterfang@mh.org.au
                Patterson.Marc@mayo.edu
                Journal
                Orphanet J Rare Dis
                Orphanet J Rare Dis
                Orphanet Journal of Rare Diseases
                BioMed Central (London )
                1750-1172
                15 August 2018
                15 August 2018
                2018
                : 13
                : 140
                Affiliations
                [1 ]ISNI 0000 0001 0663 8628, GRID grid.411160.3, Fundacio Hospital Sant Joan de Déu, ; Barcelona, Spain
                [2 ]Florey Institute of Neuroscience and Mental Health, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia
                [3 ]ISNI 0000 0004 0459 167X, GRID grid.66875.3a, Mayo Clinic, ; Rochester, MN USA
                [4 ]ISNI 0000 0001 0663 8628, GRID grid.411160.3, Hospital Sant Joan de Déu, ; Passeig de Sant Joan de Déu No. 2, Esplugues, 8950 Barcelona, Spain
                Article
                844
                10.1186/s13023-018-0844-0
                6094874
                30111334
                06c68bd2-84d7-4c95-bafd-34e9e1c5fb6a
                © The Author(s). 2018

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 13 February 2018
                : 14 June 2018
                Categories
                Review
                Custom metadata
                © The Author(s) 2018

                Infectious disease & Microbiology
                niemann-pick disease type c,miglustat,efficacy,biomarker
                Infectious disease & Microbiology
                niemann-pick disease type c, miglustat, efficacy, biomarker

                Comments

                Comment on this article